Rallybio downgraded by Jefferies with a new price target
$RLYB
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies downgraded Rallybio from Buy to Hold and set a new price target of $1.50 from $7.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/9/2025 | Buy → Neutral | H.C. Wainwright | |
| 5/15/2024 | Overweight → Neutral | JP Morgan | |
| 2/7/2024 | $7.00 → $1.50 | Buy → Hold | Jefferies |
| 4/17/2023 | $18.00 | Buy | H.C. Wainwright |
| 4/10/2023 | $17.00 | Outperform | Wedbush |
| 12/9/2022 | $21.00 | Overweight | JP Morgan |
| 2/22/2022 | $32.00 | Mkt Outperform | JMP Securities |
| 8/23/2021 | $40.00 | Outperform | Evercore ISI Group |
4 - Rallybio Corp (0001739410) (Issuer)
4 - Rallybio Corp (0001739410) (Issuer)
4 - Rallybio Corp (0001739410) (Issuer)
8-K - Rallybio Corp (0001739410) (Filer)
8-K - Rallybio Corp (0001739410) (Filer)
S-8 - Rallybio Corp (0001739410) (Filer)
H.C. Wainwright downgraded Rallybio from Buy to Neutral
JP Morgan downgraded Rallybio from Overweight to Neutral
Jefferies downgraded Rallybio from Buy to Hold and set a new price target of $1.50 from $7.00 previously